Adventure travel and type 1 diabetes: The complicating effects of high altitude

Diabetes Care

Volumn 28, Issue 10, 2005, Pages 2563-2572

  Brubaker, Patricia L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BISMUTH SALICYLATE; DEXAMETHASONE; GLUCOCORTICOID; ORAL REHYDRATION SOLUTION;

ADRENERGIC SYSTEM; ALTITUDE DISEASE; ALTITUDE INDUCED ANOREXIA; ANOREXIA; BRAIN EDEMA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEVICE; DIABETES CONTROL; DRUG EFFICACY; DRUG MEGADOSE; ENVIRONMENTAL TEMPERATURE; FOOD; GLUCOSE METER; HEALTH CARE AVAILABILITY; HIGH ALTITUDE BRAIN EDEMA; HIGH ALTITUDE LUNG EDEMA; HIGH ALTITUDE RETINA HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KETOACIDOSIS; LUNG EDEMA; RETINA HEMORRHAGE; REVIEW; TRAVEL; TRAVELLER DIARRHEA; VACCINATION;

ALTITUDE SICKNESS; ANOREXIA; DIABETES MELLITUS, TYPE 1; HUMANS; MOUNTAINEERING; TRAVEL;

EID: 25644436428     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.10.2563     Document Type: Review

References (78)

1. Steppel JH, Horton ES: Exercise in the management of type 1 diabetes mellitus. Rev Endocr Metab Disord 4:355-360, 2003
2. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C: Physical activity/exercise and type 2 diabetes. Diabetes Care 27: 2518-2539, 2004
3. Herter CD: DKA on Mt. Rainier: a case report. Diabetes Spectrum 12:198-201, 1999
4. Moore K, Vizzard N, Coleman C, McMahon J, Hayes R, Thompson CJ: Extreme altitude mountaineering and type 1 diabetes: the Diabetes Federation of Ireland Kilimanjaro Expedition. Diabet Med 18: 749-755, 2001
5. Moore K, Thompson C, Hayes R: Diabetes and extreme altitude mountaineering. Br J Sports Med 35:83, 2001
6. Admetlla J, Leal C, Ricart A: Management of diabetes at high altitude. Br J Sports Med 35:282-283, 2001
7. Admetlla J, Leal C, Ricart de Mesones A: Diabetes mellitus and mountain sports [article online], 2001. Available from http://idea2000.org/moreinfo/docs/ diab& mountains.pdf
8. Pavan P, Sarto P, Merlo L, Casara D, Ponchia A, Biasin R, Noventa D, Avogaro A: Extreme altitude mountaineering and type 1 diabetes: the Cho Oyu alpinisti in Alta Quota expedition. Diabetes Care 26: 3196-3197, 2003
9. Hillebrandt D: Six selected cases from a year's experience as advisory doctor to a commercial mountaineering expedition company. High Alt Med Biol 4:93-98, 2003
10. Pavan P, Sarto P, Merlo L, Casara D, Ponchia A, Biasin R, Noventa D, Avogaro A: Metabolic and cardiovascular parameters in type 1 diabetes at extreme altitude. Med Sci Sports Exerc 36:1283-1289, 2004
11. West JB: The physiologic basis of high-altitude diseases. Ann Intern Med 141: 789-800, 2004
12. Veves A, Saouaf R, Donaghue VM, Mullooly CA, Kistler JA, Giurini JM, Horton ES, Fielding RA: Aerobic exercise capacity remains normal despite impaired endothelial function in the micro- and macrocirculation of physically active IDDM patients. Diabetes 46:1846-1852, 1997
13. Roach RC, Bartsch P, Hackett PH, Olez Ó: The Lake Louise acute mountain sickness scoring system. In Hypoxia and Molecular Medicine. 1st ed. Sutton JR, Houston CS, Coates G, Eds. Burlington, VT, Queen City Printers, 1993, p. 52-59
14. Savourey G, Guinet A, Besnard Y, Garcia N, Hanniquet AM, Bittel J: Evaluation of the Lake Louise acute mountain sickness scoring system in a hypobaric chamber. Aviat Space Environ Med 66:963-967, 1995
15. Roach RC, Hackett PH: Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 204:3161-3170, 2001
16. Basnyat B, Murdoch DR: High-altitude illness. Lancet 361:1967-1974, 2003
17. Gallagher SA, Hackett PH: High-altitude illness. Emerg Med Clin North Am 22:329-355, viii, 2004
18. Hackett PH, Rennie D: Rales, peripheral edema, retinal hemorrhage and acute mountain sickness. Am J Med 67:214-218, 1979
19. Mader TH, Tabin G: Going to high altitude with preexisting ocular conditions. High Alt Med Biol 4:419-430, 2003
20. Maggiorini M, Buhler B, Walter M, Oelz O: Prevalence of acute mountain sickness in the Swiss Alps. Br Med J 301:853-855, 1990
21. Rodway GW, Hoffman LA, Sanders MH: High-altitude-related disorders. Part 1. Pathophysiology, differential diagnosis, and treatment. Heart Lung 32:353-359, 2003
22. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C: Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol 4:45-52, 2003
23. Dumont L, Mardirosoff C, Tramer MR: Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 321: 267-272, 2000
24. Filippi L, Bagnoli F, Margollicci M, Zammarchi E, Tronchin M, Rubaltelli FF: Pathogenic mechanism, prophylaxis, and therapy of symptomatic acidosis induced by acetazolamide. J Investig Med 50:125-132, 2002
25. Basu M, Sawhney RC, Kumar S, Pal K, Prasad R, Selvamurthy W: Glucocorticoids as prophylaxis against acute mountain sickness. Clin Endocrinol (Oxf) 57: 761-767, 2002
26. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S: The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A 89:6035-6039, 1992
27. Perry CG, Spiers A, Cleland SJ, Lowe GD, Petrie JR, Connell JM: Glucocorticoids and insulin sensitivity: dissociation of insulin's metabolic and vascular actions. J Clin Endocrinol Metab 88:6008-6014, 2003
28. Wiedman M, Tabin GC: High-altitude retinopathy and altitude illness. Ophthalmology 106:1924-1926, 1999
29. Mairbaurl H, Schobersberger W, Hasibeder W, Knapp E, Hopferwieser T, Humpeler E, Loeffler HD, Wetzels E, Wybitul K, Baumgartl P: Exercise performance of hemodialysis patients during short-term and prolonged exposure to altitude. Clin Nephrol 32:31-39, 1989
30. Case discussion: impaired renal function and tolerance to high altitude. High Alt Med Biol 3:293-295, 2002
31. Swenson ER: ACE inhibitors and high altitude. High Alt Med Biol 5:92-94, 2004
32. Redberg RF, Greenland P, Fuster V, Pyorala K, Blair SN, Folsom AR, Newman AB, O'Leary DH, Orchard TJ, Psaty B, Schwartz JS, Starke R, Wilson PW: Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group III: risk assessment in persons with diabetes. Circulation 105:e144-e152, 2002
33. Wyss CA, Koepfli P, Fretz G, Seebauer M, Schirlo C, Kaufmann PA: Influence of altitude exposure on coronary flow reserve. Circulation 108:1202-1207, 2003
34. Faulhaber M, Flatz M, Burtscher M: Beta-blockers may provoke oxygen desaturation during submaximal exercise at moderate altitudes in elderly persons. High Alt Med Biol 4:475-478, 2003
35. Alexander JK: Coronary problems associated with altitude and air travel. Cardiol Clin 13:271-278, 1995
36. Brooks GA, Butterfield GE, Wolfe RR, Groves BM, Mazzeo RS, Sutton JR, Wolfel EE, Reeves JT: Increased dependence on blood glucose after acclimatization to 4,300 m. J Appl Physiol 70:919-927, 1991
37. Roberts AC, Reeves JT, Butterfield GE, Mazzeo RS, Sutton JR, Wolfel EE, Brooks GA: Altitude and beta-blockade augment glucose utilization during submaximal exercise. J Appl Physiol 80:605-615, 1996
38. Larsen JJ, Hansen JM, Olsen NV, Galbo H, Dela F: The effect of altitude hypoxia on glucose homeostasis in men. J Physiol 504: 241-249, 1997
39. Braun B, Butterfield GE, Dominick SB, Zamudio S, McCullough RG, Rock PB, Moore LG: Women at altitude: changes in carbohydrate metabolism at 4,300-m elevation and across the menstrual cycle. J Appl Physiol 85:1966-1973, 1998
40. Mazzeo RS, Carroll JD, Butterfield GE, Braun B, Rock PB, Wolfel EE, Zamudio S, Moore LG: Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude. J Appl Physiol 90:121-126, 2001
41. Braun B, Rock PB, Zamudio S, Wolfel GE, Mazzeo RS, Muza SR, Fulco CS, Moore LG, Butterfield GE: Women at altitude: short-term exposure to hypoxia and/or alpha(1)-adrenergic blockade reduces insulin sensitivity. J Appl Physiol 91:623-631, 2001
42. Antezana AM, Kacimi R, Le Trong JL, Marchal M, Abousahl I, Dubray C, Richalet JP: Adrenergic status of humans during prolonged exposure to the altitude of 6,542 m. J Appl Physiol 76:1055-1059, 1994
43. Reeves JT, Wolfel EE, Green HJ, Mazzeo RS, Young AJ, Sutton JR, Brooks GA: Oxygen transport during exercise at altitude and the lactate paradox: lessons from Operation Everest II and Pikes Peak. Exerc Sport Sci Rev 20:275-296, 1992
44. Halter JB, Beard JC, Porte D Jr: Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. Am J Physiol 247:E47-E52, 1984
45. Andrews RC, Walker BR: Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 96:513-523, 1999
46. Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 26:1902-1912, 2003
47. Giordano BP, Thrash W, Hollenbaugh L, Dube WP, Hodges C, Swain A, Banion CR, Klingensmith GJ: Performance of seven blood glucose testing systems at high altitude. Diabetes Educ 15:444-448, 1989
48. Gautier JF, Bigard AX, Douce P, Duvallet A, Cathelineau G: Influence of simulated altitude on the performance of five blood glucose meters. Diabetes Care 19:1430-1433, 1996
49. Pecchio O, Maule S, Migliardi M, Trento M, Veglio M: Effects of exposure at an altitude of 3,000 m on performance of glucose meters. Diabetes Care 23:129-131, 2000
50. Williams RA: Blood glucose monitoring at high altitudes. Diabetes Spectrum 13:79, 2000
51. Fink KS, Christensen DB, Ellsworth A: Effect of high altitude on blood glucose meter performance. Diabetes Technol Ther 4:627-635, 2002
52. Oberg D, Ostenson CG: Performance of glucose dehydrogenase- and glucose oxidase-based blood glucose meters at high altitude and low temperature (Letter). Diabetes Care 28:1261, 2005
53. Westerterp KR: Energy and water balance at high altitude. News Physiol Sci 16:134-137, 2001
54. Butterfield GE, Gates J, Fleming S, Brooks GA, Sutton JR, Reeves JT: Increased energy intake minimizes weight loss in men at high altitude. J Appl Physiol 72:1741-1748, 1992
55. Westerterp KR, Kayser B, Wouters L, Le Trong JL, Richalet JP: Energy balance at high altitude of 6,542 m. J Appl Physiol 77:862-866, 1994
56. Pulfrey SM, Jones PJ: Energy expenditure and requirement while climbing above 6,000 m. J Appl Physiol 81:1306-1311, 1996
57. Tschop M, Strasburger CJ, Hartmann G, Biollaz J, Bartsch P: Raised leptin concentrations at high altitude associated with loss of appetite. Lancet 352:1119-1120, 1998
58. Tschop M, Strasburger CJ, Topfer M, Hautmann H, Riepl R, Fischer R, Hartmann G, Morrison K, Appenzeller M, Hildebrandt W, Biollaz J, Bartsch P: Influence of hypobaric hypoxia on leptin levels in men. Int J Obes Relat Metab Disord 24 (Suppl. 2):S151, 2000
59. Vats P, Singh SN, Shyam R, Singh VK, Singh SB, Banerjee PK, Selvamurthy W: Leptin may not be responsible for high altitude anorexia. High Alt Med Biol 5:90-92, 2004
60. Zaccaria M, Ermolao A, Bonvicini P, Travain G, Varnier M: Decreased serum leptin levels during prolonged high altitude exposure. Eur J Appl Physiol 92:249-253, 2004
61. Bailey DM, Ainslie PN, Jackson SK, Richardson RS, Ghatei M: Evidence against redox regulation of energy homoeostasis in humans at high altitude. Clin Sci (Lond) 107:589-600, 2004
62. Cammisotto PG, Bukowiecki LJ: Mechanisms of leptin secretion from white adipocytes. Am J Physiol Cell Physiol 283: C244-C250, 2002
63. Syme D: Position paper: on-site treatment of frostbite for mountaineers. High Alt Med Biol 3:297-298, 2002
64. Grajower MM, Fraser CG, Holcombe JH, Daugherty ML, Harris WC, De Felippis MR, Santiago OM, Clark NG: How long should insulin be used once a vial is started? Diabetes Care 26:2665-2666, 2003 [discussion 266-269]
65. Midthjell K, Kapelrud H, Bjornerud A, Claudi T, Bjorgaas M, Jervell J: Severe or life-threatening hypoglycemia in insulin pump treatment. Diabetes Care 17:1235-1236, 1994
66. Prendergast JJ, Dorsey C, Elsea V: Overdelivery of insulin by insulin pumps. Diabetes Care 18:1201-1202, 1995
67. Virk A: Medical advice for international travelers. Mayo Clin Proc 76:831-840, 2001
68. American Diabetes Association: Insulin administration (Practice Guideline). Diabetes Care 27 (Suppl. 1):S106-S109, 2004
69. Peer AK, Hoosen AA, Seedat MA, van den EJ, Omar MA: Vaginal yeast infections in diabetic women. S Afr Med J 83:727-729, 1993
70. Stapleton A: Urinary tract infections in patients with diabetes. Am J Med 113 (Suppl. 1A):80S-84S, 2002
71. Mayser P, Hensel J, Thoma W, Podobinska M, Geiger M, Ulbricht H, Haak T: Prevalence of fungal foot infections in patients with diabetes mellitus type 1: underestimation of moccasin-type tinea. Exp Clin Endocrinol Diabetes 112:264-268, 2004
72. Armstrong DG, Lipsky BA: Advances in the treatment of diabetic foot infections. Diabetes Technol Ther 6:167-177, 2004
73. Ericsson CD: Travellers' diarrhoea. Int J Antimicrob Agents 21:116-124, 2003
74. Food and Drug Administration, HHS: Antidiarrheal drug products for over-the-counter human use: amendment of final monograph. Final rule. Fed Regist 69: 26301-26302, 2004
75. Raider R, Azad Khan AK, Roy SK, Dewan N, Alam AN, Mahalanabis D: Management of acute diarrhoea in diabetic patients using oral rehydration solutions containing glucose, rice, or glycine. Br Med J 308:624-626, 1994
76. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 28:S4-S36, 2005
77. Guerrant RL, Carneiro-Filho BA, Dillingham RA: Cholera, diarrhea, and oral rehydration therapy: triumph and indictment. Clin Infect Dis 37:398-405, 2003
78. American Diabetes Association: Management of diabetes at diabetes camps (Position Statement). Diabetes Care 22:167-169, 1999